Cargando…

Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy

Background: The concern for adverse events following immunization (AEFI) and anti-vaccination movements that lacked scientific evidence-based supports may reduce vaccine uptake in the general population. Thus, the aims of the present study were to characterize AEFI in general population (all age gro...

Descripción completa

Detalles Bibliográficos
Autores principales: Lombardi, Niccolò, Crescioli, Giada, Bettiol, Alessandra, Tuccori, Marco, Rossi, Marco, Bonaiuti, Roberto, Ravaldi, Claudia, Levi, Miriam, Mugelli, Alessandro, Ricci, Silvia, Lippi, Francesca, Azzari, Chiara, Bonanni, Paolo, Vannacci, Alfredo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728926/
https://www.ncbi.nlm.nih.gov/pubmed/31543816
http://dx.doi.org/10.3389/fphar.2019.00948
_version_ 1783449504959168512
author Lombardi, Niccolò
Crescioli, Giada
Bettiol, Alessandra
Tuccori, Marco
Rossi, Marco
Bonaiuti, Roberto
Ravaldi, Claudia
Levi, Miriam
Mugelli, Alessandro
Ricci, Silvia
Lippi, Francesca
Azzari, Chiara
Bonanni, Paolo
Vannacci, Alfredo
author_facet Lombardi, Niccolò
Crescioli, Giada
Bettiol, Alessandra
Tuccori, Marco
Rossi, Marco
Bonaiuti, Roberto
Ravaldi, Claudia
Levi, Miriam
Mugelli, Alessandro
Ricci, Silvia
Lippi, Francesca
Azzari, Chiara
Bonanni, Paolo
Vannacci, Alfredo
author_sort Lombardi, Niccolò
collection PubMed
description Background: The concern for adverse events following immunization (AEFI) and anti-vaccination movements that lacked scientific evidence-based supports may reduce vaccine uptake in the general population. Thus, the aims of the present study were to characterize AEFI in general population (all age groups), in terms of frequency, preventability, and seriousness and to define predictors of their seriousness in children. Methods: A retrospective study was performed on suspected AEFI reports for children and adults who received any form of vaccinations, collected in Tuscany, Italy, between 1 January and 31 December 2017. Patients’ characteristics, suspected vaccines, and AEFI description were collected. Causality and preventability were assessed using WHO and Schumock and Thornton algorithms, respectively. Logistic regression was used to estimate the reporting odds ratios of potential predictors of AEFI seriousness in children. Results: A total of 223 suspected AEFI reports were collected, and the majority of them were defined as non-serious (76.7%). Reports were mostly related to one vaccine, and to a median of two to five strains/toxoids. The total number of simultaneously administered strains/toxoids and the presence of allergens did not correlate with AEFI seriousness. Considering vaccines with a high number of administered doses (≥60,000 doses), the rates estimated for serious AEFI reports were always very low, ranging between 0.01 and 0.2/1,000 doses. Twenty-four vaccines (8,993 doses) were not related to any AEFI. Conclusion: Results of present study showed that AEFI were very rare; the vast majority of them was non-serious and, despite the claims of anti-vaccination movements, the simultaneous administration of vaccines was safe and did not influence the risk of reporting a serious AEFI, particularly in children.
format Online
Article
Text
id pubmed-6728926
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-67289262019-09-20 Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy Lombardi, Niccolò Crescioli, Giada Bettiol, Alessandra Tuccori, Marco Rossi, Marco Bonaiuti, Roberto Ravaldi, Claudia Levi, Miriam Mugelli, Alessandro Ricci, Silvia Lippi, Francesca Azzari, Chiara Bonanni, Paolo Vannacci, Alfredo Front Pharmacol Pharmacology Background: The concern for adverse events following immunization (AEFI) and anti-vaccination movements that lacked scientific evidence-based supports may reduce vaccine uptake in the general population. Thus, the aims of the present study were to characterize AEFI in general population (all age groups), in terms of frequency, preventability, and seriousness and to define predictors of their seriousness in children. Methods: A retrospective study was performed on suspected AEFI reports for children and adults who received any form of vaccinations, collected in Tuscany, Italy, between 1 January and 31 December 2017. Patients’ characteristics, suspected vaccines, and AEFI description were collected. Causality and preventability were assessed using WHO and Schumock and Thornton algorithms, respectively. Logistic regression was used to estimate the reporting odds ratios of potential predictors of AEFI seriousness in children. Results: A total of 223 suspected AEFI reports were collected, and the majority of them were defined as non-serious (76.7%). Reports were mostly related to one vaccine, and to a median of two to five strains/toxoids. The total number of simultaneously administered strains/toxoids and the presence of allergens did not correlate with AEFI seriousness. Considering vaccines with a high number of administered doses (≥60,000 doses), the rates estimated for serious AEFI reports were always very low, ranging between 0.01 and 0.2/1,000 doses. Twenty-four vaccines (8,993 doses) were not related to any AEFI. Conclusion: Results of present study showed that AEFI were very rare; the vast majority of them was non-serious and, despite the claims of anti-vaccination movements, the simultaneous administration of vaccines was safe and did not influence the risk of reporting a serious AEFI, particularly in children. Frontiers Media S.A. 2019-08-30 /pmc/articles/PMC6728926/ /pubmed/31543816 http://dx.doi.org/10.3389/fphar.2019.00948 Text en Copyright © 2019 Lombardi, Crescioli, Bettiol, Tuccori, Rossi, Bonaiuti, Ravaldi, Levi, Mugelli, Ricci, Lippi, Azzari, Bonanni and Vannacci http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Lombardi, Niccolò
Crescioli, Giada
Bettiol, Alessandra
Tuccori, Marco
Rossi, Marco
Bonaiuti, Roberto
Ravaldi, Claudia
Levi, Miriam
Mugelli, Alessandro
Ricci, Silvia
Lippi, Francesca
Azzari, Chiara
Bonanni, Paolo
Vannacci, Alfredo
Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy
title Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy
title_full Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy
title_fullStr Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy
title_full_unstemmed Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy
title_short Vaccines Safety in Children and in General Population: A Pharmacovigilance Study on Adverse Events Following Anti-Infective Vaccination in Italy
title_sort vaccines safety in children and in general population: a pharmacovigilance study on adverse events following anti-infective vaccination in italy
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6728926/
https://www.ncbi.nlm.nih.gov/pubmed/31543816
http://dx.doi.org/10.3389/fphar.2019.00948
work_keys_str_mv AT lombardiniccolo vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT crescioligiada vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT bettiolalessandra vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT tuccorimarco vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT rossimarco vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT bonaiutiroberto vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT ravaldiclaudia vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT levimiriam vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT mugellialessandro vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT riccisilvia vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT lippifrancesca vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT azzarichiara vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT bonannipaolo vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly
AT vannaccialfredo vaccinessafetyinchildrenandingeneralpopulationapharmacovigilancestudyonadverseeventsfollowingantiinfectivevaccinationinitaly